25 research outputs found
Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast
Micropapillary carcinoma ( MPC ) is a rare histological special type of breast cancer, characterized by an aggressive clinical behaviour and a pattern of copy number aberrations ( CNAs ) distinct from that of gradeâ and oestrogen receptor ( ER )âmatched invasive carcinomas of no special type ( ICâNSTs ). The aims of this study were to determine whether MPCs are underpinned by a recurrent fusion gene(s) or mutations in 273 genes recurrently mutated in breast cancer. Sixteen MPCs were subjected to microarrayâbased comparative genomic hybridization ( aCGH ) analysis and Sequenom OncoCarta mutation analysis. Eight and five MPCs were subjected to targeted capture and RNA sequencing, respectively. aCGH analysis confirmed our previous observations about the repertoire of CNAs of MPCs . Sequencing analysis revealed a spectrum of mutations similar to those of luminal B ICâNSTs , and recurrent mutations affecting mitogenâactivated protein kinase family genes and NBPF10 . RNA âsequencing analysis identified 17 highâconfidence fusion genes, eight of which were validated and two of which were inâframe. No recurrent fusions were identified in an independent series of MPCs and ICâNSTs . Forced expression of inâframe fusion genes ( SLC2A1âFAF1 and BCAS4âAURKA ) resulted in increased viability of breast cancer cells. In addition, genomic disruption of CDK12 caused by outâofâframe rearrangements was found in one MPC and in 13% of HER2 âpositive breast cancers, identified through a reâanalysis of publicly available massively parallel sequencing data. In vitro analyses revealed that CDK12 gene disruption results in sensitivity to PARP inhibition, and forced expression of wildâtype CDK12 in a CDK12 ânull cell line model resulted in relative resistance to PARP inhibition. Our findings demonstrate that MPCs are neither defined by highly recurrent mutations in the 273 genes tested, nor underpinned by a recurrent fusion gene. Although seemingly private genetic events, some of the fusion transcripts found in MPCs may play a role in maintenance of a malignant phenotype and potentially offer therapeutic opportunities. © 2014 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/106752/1/path4325.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/106752/2/path4325-sup-0001-AppendixS1.pd
Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification
Background HER2 is overexpressed and amplified in approximately 15% of invasive breast cancers, and is the molecular target and predictive marker of response to anti-HER2 agents. In a subset of these cases, heterogeneous distribution of HER2 gene amplification can be found, which creates clinically challenging scenarios. Currently, breast cancers with HER2 amplification/overexpression in just over 10% of cancer cells are considered HER2-positive for clinical purposes; however, it is unclear as to whether the HER2-negative components of such tumors would be driven by distinct genetic alterations. Here we sought to characterize the pathologic and genetic features of the HER2-positive and HER2-negative components of breast cancers with heterogeneous HER2 gene amplification and to define the repertoire of potential driver genetic alterations in the HER2-negative components of these cases.Results We separately analyzed the HER2-negative and HER2-positive components of 12 HER2 heterogeneous breast cancers using gene copy number profiling and massively parallel sequencing, and identified potential driver genetic alterations restricted to the HER2-negative cells in each case. In vitro experiments provided functional evidence to suggest that BRF2 and DSN1 overexpression/amplification, and the HER2 I767M mutation may be alterations that compensate for the lack of HER2 amplification in the HER2-negative components of HER2 heterogeneous breast cancers.Conclusions Our results indicate that even driver genetic alterations, such as HER2 gene amplification, can be heterogeneously distributed within a cancer, and that the HER2-negative components are likely driven by genetic alterations not present in the HER2-positive components, including BRF2 and DSN1 amplification and HER2 somatic mutations
Comparative proteomic assessment of matrisome enrichment methodologies
The matrisome is a complex and heterogeneous collection of extracellular matrix (ECM) and ECM-associated proteins that play important roles in tissue development and homeostasis. While several strategies for matrisome enrichment have been developed, it is currently unknown how the performance of these different methodologies compares in the proteomic identification of matrisome components across multiple tissue types. In the present study, we perform a comparative proteomic assessment of two widely used decellularisation protocols and two extraction methods to characterise the matrisome in four murine organs (heart, mammary gland, lung and liver). We undertook a systematic evaluation of the performance of the individual methods on protein yield, matrisome enrichment capability and the ability to isolate core matrisome and matrisome-associated components. Our data find that sodium dodecyl sulphate (SDS) decellularisation leads to the highest matrisome enrichment efficiency, while the extraction protocol that comprises chemical and trypsin digestion of the ECM fraction consistently identifies the highest number of matrisomal proteins across all types of tissue examined. Matrisome enrichment had a clear benefit over non-enriched tissue for the comprehensive identification of matrisomal components in murine liver and heart. Strikingly, we find that all four matrisome enrichment methods led to significant losses in the soluble matrisome-associated proteins across all organs. Our findings highlight the multiple factors (including tissue type, matrisome class of interest and desired enrichment purity) that influence the choice of enrichment methodology, and we anticipate that these data will serve as a useful guide for the design of future proteomic studies of the matrisome
Effect of electron-beam irradiation and vitamin E fortified diet on ground beef quality preservation
The effects of electron-beam irradiation (EBI) treatment and dietary vitamin E
supplementation on microbial and organoleptic quality of ground beef patties were
investigated during 21 days refrigerated (4°C) and 6 months frozen (-22°C) storage.
Ground beef patties were prepared from meat from cattle fed basal (diet I) and vitamin E
supplemented diets (diet II). Plasma vitamin E concentration in cattle fed diets I and II
were 1.58 ± 0.42 and from 2.49 ± 0.53 to 2.91 ± 0.57 Όg vitamin E/ml plasma,
respectively. Patties were then processed with 4 different doses of electron-beam
irradiation (0, 2, 5, 10 kGy).
Microbial indices monitored at 3-day intervals throughout a 21-day storage period
at 4°C and at 1-month intervals during a 6-months storage period at -22°C, included Total
Aerobic Plate Count (TAPC), Psychrotroph Counts and Total Coliform and E. coli
Counts. Total aerobic and psychrotrophic bacterial growth in ground beef patties stored
at 4°C and -22°C were significantly (P < 0.05) reduced by EBI at 2 kGy. Complete
inhibition of bacteria occurred at 5 kGy or higher (P < 0.05) dosages of EBI. Beef patties
made from steers fed vitamin E (diet II) were found to have a higher (P < 0.05) TAPC
and Psychrotrophic bacteria than patties derived from animals fed the basal diet (diet I).
From the growth pattern of the two detected classes of microorganisms, psychrotrophic
bacteria appeared to recover faster from irradiation stress, and were able to grow more
rapidly upon storage than the aerobic bacteria. Neither Coliforms nor E.coli were not
detectable in the beef samples during the experimental period due to a low initial count.
Parameters such as pH and water activity (a[sub w]) were also measured.
Chemical and instrumental indices monitored at 3-day intervals throughout a 21-
day storage period at 4°C, and at 1-month intervals during a 6-months storage period at -
22°C included thiobarbituric acid reactive substances (TBARS), color, and texture.
Moisture, total crude lipid content and fatty acid compositions were monitored at 7-day
intervals throughout a 21-day storage period at 4°C and at 1-month intervals during a 6-
months storage period at -22°C. Results indicated that irradiation was associated with
higher (P < 0.05) TBA values and greater (P < 0.05) shear force. TBA values of beef
patties reached peak levels on Day 9 in 4°C storage and at Month 3 in -22°C storage,
respectively. No significant differences were observed in shear values of beef patties
irradiated at different doses. With all four levels of irradiation, Hunter a values of beef
patties decreased (P < 0.05) significantly, and this effect could be observed immediately
after irradiation. Lipid oxidation was significantly retarded in stored beef patties derived
from cattle fed vitamin E (diet II). These results indicate that electron beam irradiation
pasteurization is an effective method to ensure microbial safety of refrigerated and frozen
ground beef patties. The application of electron beam irradiation and vitamin E
supplemented diet significantly improved ground beef safety and lipid stability during
storage at 4°C and -22°C.Land and Food Systems, Faculty ofGraduat
Applications of the GIS to urban design in Hong Kong
published_or_final_versionUrban DesignMasterMaster of Urban Desig
SF3B1 mutations constitute a novel therapeutic target in breast cancer
Mutations in genes encoding proteins involved in RNA splicing have been found to occur at relatively high frequencies in several tumour types including myelodysplastic syndromes, chronic lymphocytic leukaemia, uveal melanoma, and pancreatic cancer, and at lower frequencies in breast cancer. To investigate whether dysfunction in RNA splicing is implicated in the pathogenesis of breast cancer, we performed a re-analysis of published exome and whole genome sequencing data. This analysis revealed that mutations in spliceosomal component genes occurred in 5.6% of unselected breast cancers, including hotspot mutations in the SF3B1 gene, which were found in 1.8% of unselected breast cancers. SF3B1 mutations were significantly associated with ER-positive disease, AKT1 mutations, and distinct copy number alterations. Additional profiling of hotspot mutations in a panel of special histological subtypes of breast cancer showed that 16% and 6% of papillary and mucinous carcinomas of the breast harboured the SF3B1 K700E mutation. RNA sequencing identified differentially spliced events expressed in tumours with SF3B1 mutations including the protein coding genes TMEM14C, RPL31, DYNL11, UQCC, and ABCC5, and the long non-coding RNA CRNDE. Moreover, SF3B1 mutant cell lines were found to be sensitive to the SF3b complex inhibitor spliceostatin A and treatment resulted in perturbation of the splicing signature. Albeit rare, SF3B1 mutations result in alternative splicing events, and may constitute drivers and a novel therapeutic target in a subset of breast cancers
Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
Background: The efficacy and safety of using combination chemotherapy with cetuximab as first-line treatment in patients with K-ras wild-type colorectal cancers has been well established. In general, weekly cetuximab was given with biweekly chemotherapy FOLFOX-4 or FOLFIRI, synchronizing them would be appealed to both patients and health care professionals. Materials and Methods: This Phase II, prospective study investigated the efficacy and safety of using biweekly cetuximab 500 mg/m 2 with chemotherapy FOLFOX-4 or FOLFIRI as first-line treatment for Chinese patients with K-ras wild-type metastatic colorectal cancer. The study endpoints included overall objective response (OR), progression-free survival (PFS), overall survival (OS) and safety. Results: Total 15 Chinese patients (male: 10 [67%]; median age: 60 [range 41-80]) were enrolled. Patients received median 12 cycles (range 2-12) of chemotherapy + cetuximab (FOLFOX-4 + cetuximab: 9 [60%]; FOLFIRI + cetuximab: 6 [40%]). Six patients (40%) with non-progressive disease after 12 cycles of chemotherapy + cetuximab carried on maintenance cetuximab. Median duration of follow-up (FU) was 23.7 months. The OR was 40% (complete response: 0%; partial response: 40%) for a disease control rate of 87%. Median PFS and OS were 7.8 months and 17.9 months respectively. For maintenance cetuximab phase, median PFS since the start of maintenance cetuximab was 6.8 months and median OS was 17.0 months. The only grade 3-4 toxicities were neutropenia (26.7%) in chemotherapy phase and acneiform rashes (16.7%) in maintenance phase. Conclusions: Biweekly cetuximab with combination chemotherapy was effective and safe as weekly dose. Further studies are warranted for the role of maintenance cetuximab